• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Drug-Tolerant Persister Cells After EGFR Tyrosine Kinase Inhibitor Treatment: Their Origin and the Influences From the Tumor Microenvironment.

作者信息

Ebi Hiromichi

机构信息

Division of Molecular Therapeutics, Aichi Cancer Center Research Institute, Nagoya, Japan; Center for Cancer Genomics and Advanced Therapeutics, Aichi Cancer Center Hospital, Nagoya, Japan; Division of Advanced Cancer Therapeutics, Nagoya University Graduate School of Medicine, Nagoya, Japan.

出版信息

J Thorac Oncol. 2023 Apr;18(4):399-401. doi: 10.1016/j.jtho.2022.12.010.

DOI:10.1016/j.jtho.2022.12.010
PMID:36990572
Abstract
摘要

相似文献

1
Drug-Tolerant Persister Cells After EGFR Tyrosine Kinase Inhibitor Treatment: Their Origin and the Influences From the Tumor Microenvironment.表皮生长因子受体酪氨酸激酶抑制剂治疗后的耐药性持久细胞：其起源及肿瘤微环境的影响
J Thorac Oncol. 2023 Apr;18(4):399-401. doi: 10.1016/j.jtho.2022.12.010.
2
Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer.靶向 FGFR 可克服 EGFR 突变型非小细胞肺癌中的 EMT 介导的耐药性。
Oncogene. 2019 Sep;38(37):6399-6413. doi: 10.1038/s41388-019-0887-2. Epub 2019 Jul 19.
3
Notch pathway regulates osimertinib drug-tolerant persistence in EGFR-mutated non-small-cell lung cancer.Notch 通路调控 EGFR 突变型非小细胞肺癌中奥希替尼耐药性的持续存在。
Cancer Sci. 2023 Apr;114(4):1635-1650. doi: 10.1111/cas.15674. Epub 2022 Dec 7.
4
Clinicopathologic Features and Immune Microenvironment of Non-Small-cell Lung Cancer With Primary Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.表皮生长因子受体酪氨酸激酶抑制剂原发性耐药的非小细胞肺癌的临床病理特征和免疫微环境。
Clin Lung Cancer. 2018 Jul;19(4):352-359.e1. doi: 10.1016/j.cllc.2018.02.004. Epub 2018 Feb 19.
5
Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment.基于 EGFR-TKI 治疗后疾病进展时 T790M 状态的肿瘤免疫微环境和纳武利尤单抗在 EGFR 突变阳性非小细胞肺癌中的疗效。
Ann Oncol. 2017 Jul 1;28(7):1532-1539. doi: 10.1093/annonc/mdx183.
6
Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.非小细胞肺癌脑转移的治疗。
Int J Mol Sci. 2021 Jan 8;22(2):593. doi: 10.3390/ijms22020593.
7
AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells.AXL 赋予了对奥希替尼的内在耐药性，并促进了耐药细胞的出现。
Nat Commun. 2019 Jan 16;10(1):259. doi: 10.1038/s41467-018-08074-0.
8
[Mechanisms of Resistance to the Third-generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer].[非小细胞肺癌对第三代表皮生长因子受体酪氨酸激酶抑制剂的耐药机制]
Zhongguo Fei Ai Za Zhi. 2018 Feb 20;21(2):110-115. doi: 10.3779/j.issn.1009-3419.2018.02.02.
9
Patient-derived xenograft models of non-small cell lung cancer for evaluating targeted drug sensitivity and resistance.非小细胞肺癌患者来源异种移植模型用于评估靶向药物敏感性和耐药性。
Cancer Sci. 2019 Oct;110(10):3215-3224. doi: 10.1111/cas.14171.
10
Does the Lung Cancer Field Need Another Third-Generation EGFR Tyrosine Kinase Inhibitor?肺癌领域还需要另一种第三代表皮生长因子受体酪氨酸激酶抑制剂吗？
J Thorac Oncol. 2020 Jun;15(6):881-883. doi: 10.1016/j.jtho.2020.02.021.

引用本文的文献

1
Personalized care for patients with EGFR-mutant nonsmall cell lung cancer: Navigating early to advanced disease management.表皮生长因子受体（EGFR）突变型非小细胞肺癌患者的个性化护理：从早期到晚期疾病管理的全程指引
CA Cancer J Clin. 2025 Sep-Oct;75(5):387-409. doi: 10.3322/caac.70024. Epub 2025 Jul 17.
2
Drug-induced tolerant persisters in tumor: mechanism, vulnerability and perspective implication for clinical treatment.肿瘤中药物诱导的耐受性持久性细胞：机制、易损性及对临床治疗的潜在意义
Mol Cancer. 2025 May 24;24(1):150. doi: 10.1186/s12943-025-02323-9.
3
Targeting of drug-tolerant persister cells as an approach to counter drug resistance in non-small cell lung cancer.
针对耐药性休眠细胞的靶向治疗作为克服非小细胞肺癌耐药性的一种方法。
Lung Cancer. 2024 Aug;194:107885. doi: 10.1016/j.lungcan.2024.107885. Epub 2024 Jul 8.
4
Leveraging Cancer Phenotypic Plasticity for Novel Treatment Strategies.利用癌症表型可塑性制定新型治疗策略。
J Clin Med. 2024 Jun 5;13(11):3337. doi: 10.3390/jcm13113337.
5
A Nexus between Genetic and Non-Genetic Mechanisms Guides KRAS Inhibitor Resistance in Lung Cancer.遗传和非遗传机制之间的联系指导肺癌中 KRAS 抑制剂耐药性。
Biomolecules. 2023 Oct 28;13(11):1587. doi: 10.3390/biom13111587.